A cost-minimization analysis of MD-Knee versus hyaluronic acid in patients with knee osteoarthritis
Autor: | Alberto Migliore; Roberto Ravasio |
---|---|
Sprache: | Englisch; Italienisch |
Veröffentlicht: |
2020 |
Quelle: | Directory of Open Access Journals: DOAJ Articles |
Online Zugang: |
https://journals.aboutscience.eu/index.php/aboutopen/article/view/2141 https://doaj.org/toc/2465-2628 doi:10.33393/abtpn.2020.2141 2465-2628 https://doaj.org/article/6f13640116514d7d86d3cac16d58b231 https://doi.org/10.33393/abtpn.2020.2141 https://doaj.org/article/6f13640116514d7d86d3cac16d58b231 |
Erfassungsnummer: | ftdoajarticles:oai:doaj.org/article:6f13640116514d7d86d3cac16d58b231 |
Zusammenfassung
Introduction: The administration by injection of hyaluronic acid (HA) for 3-5 weeks is effective in the treatment of patients with knee osteoarthritis (OA). Other products for intra-articular use have been recently introduced for the treatment of OA. Among these, a medical device, MD-Knee, produced by Guna S.p.A.; this study aims to estimate the cost-minimization of MD-Knee versus HA in the treatment of knee osteoarthritis. Methods and Results: We performed a cost-minimization analysis (CMA). The CMA was conducted from the perspective of the Italian National Health Service (iNHS). Only direct medical costs (MD-Knee and HA) were considered. We performed a sensitivity analysis to test the robustness of the results. The mean 6-months cost per patient was € 75,00 with MD-Knee and € 185,00 with HA. Conclusion: From the Italian National Health Service’s perspective, MD-Knee appears to be the cost-saving therapeutic option compared with HA in the treatment of patients with knee osteoarthritis.